Cetera Investment Advisers Has $1.12 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Cetera Investment Advisers lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 66.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,770 shares of the biopharmaceutical company's stock after acquiring an additional 1,902 shares during the quarter. Cetera Investment Advisers' holdings in Alnylam Pharmaceuticals were worth $1,122,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Capital World Investors grew its position in shares of Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock valued at $3,906,284,000 after purchasing an additional 92,101 shares during the last quarter. Vanguard Group Inc. grew its holdings in Alnylam Pharmaceuticals by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock valued at $2,996,296,000 after buying an additional 98,303 shares during the last quarter. Capital Research Global Investors grew its holdings in Alnylam Pharmaceuticals by 32.9% in the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after buying an additional 1,724,610 shares during the last quarter. Regeneron Pharmaceuticals Inc. bought a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 39.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after buying an additional 1,245,195 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on ALNY shares. Canaccord Genuity Group boosted their target price on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. UBS Group increased their target price on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. HC Wainwright reaffirmed a "buy" rating and issued a $500.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Finally, JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $280.00 to $328.00 in a research report on Monday, March 24th. One research analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have assigned a buy rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $319.17.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY traded down $2.44 during mid-day trading on Wednesday, reaching $287.66. 301,322 shares of the company were exchanged, compared to its average volume of 878,974. Alnylam Pharmaceuticals, Inc. has a 12 month low of $146.79 and a 12 month high of $304.39. The stock has a market cap of $37.51 billion, a PE ratio of -132.66 and a beta of 0.17. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The company has a fifty day moving average of $259.82 and a 200 day moving average of $254.53.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to analysts' expectations of $584.32 million. Alnylam Pharmaceuticals's revenue was up 20.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.16) EPS. On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.